Introduction {#Sec1}
============

Mixed dyslipidemia, characterized by elevated levels of triglycerides (TG), low levels of high-density lipoprotein cholesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), and a preponderance of small dense particles is associated with additional coronary heart disease (CHD) risk, compared with elevated LDL-C alone \[[@CR1]--[@CR4]\]. National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III identifies both elevated TG and low levels of HDL-C as markers of increased cardiovascular risk given that each is independently associated with CHD risk \[[@CR5]\]. Although LDL-C remains the primary therapeutic target in the management of dyslipidemia, NCEP ATP III also recommends non--HDL-C as a secondary target of treatment in patients at LDL-C goal with persistent hypertriglyceridemia (TG ≥ 200 mg/dL). As an alternative to intensifying LDL-C--lowering therapy or if tolerance to a statin becomes an issue, the addition of nicotinic acid or a fibrate to LDL-C--lowering treatment is recommended to achieve a non--HDL-C goal no higher than 30 mg/dL above the patient's LDL-C goal \[[@CR5]\].

The choline salt of fenofibric acid formulated as enteric-coated mini-tablets in a delayed-release capsule (Trilipix, Abbott, Abbott Park, IL) is indicated for combined use with a statin to reduce TG and increase HDL-C in CHD or a CHD risk equivalent patients with mixed dyslipidemia who are on optimal statin therapy to achieve their LDL-C goal. In three similarly designed 12-week, controlled clinical studies, fenofibric acid coadministered with low- or moderate-dose rosuvastatin, simvastatin, or atorvastatin was found to be efficacious and well tolerated in patients with mixed dyslipidemia \[[@CR6]--[@CR8]\]. A subsequent 52-week, open-label extension of the three controlled studies evaluated the long-term safety and efficacy of fenofibric acid coadministered with moderate-dose statin \[[@CR9]\]. This analysis of the extension study evaluated the long-term efficacy of adding fenofibric acid 135 mg to moderate-dose statin therapy (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) in patients with LDL-C \<100 mg/dL but with TG above 200 mg/dL after 12 weeks of treatment with moderate-dose statin monotherapy in the controlled studies.

Methods {#Sec2}
=======

This is a post hoc analysis of data collected during a 52-week open-label extension study of three similarly designed phase 3, 12-week, multicenter, randomized, controlled, double-blind studies (NCT00300482, NCT00300469, NCT00300456). The studies were conducted between March, 2006 and March, 2008. All patients provided written informed consent and the studies were approved by the institutional review board at each center. Eligible patients for the three controlled studies were adults ≥18 years of age with mixed dyslipidemia defined as screening TG ≥ 150 mg/dL, LDL-C ≥ 130 mg/dL, and HDL-C \<40 mg/dL for men and \<50 mg/dL for women. Exclusion criteria included pregnancy, evidence of unstable cardiovascular disease, type 1 diabetes mellitus, and uncontrolled type 2 diabetes mellitus with hemoglobin A1c \>8.5%. Patients who completed the controlled studies were eligible to enroll in the open-label extension study.

Details of the study design for the three controlled studies and the open-label extension study have been published previously (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6]--[@CR9]\]. Each controlled study used a separate statin (rosuvastatin, simvastatin, or atorvastatin). Briefly, in these controlled studies, after a 6-week diet run-in/lipid therapy washout period, patients meeting the eligibility criteria were randomized to 12 weeks of blinded treatment with fenofibric acid 135 mg; monotherapy with low- (rosuvastatin 10 mg, simvastatin 20 mg, and atorvastatin 20 mg), moderate- (rosuvastatin 20 mg, simvastatin 40 mg, and atorvastatin 40 mg), or high-dose (rosuvastatin 40 mg, simvastatin 80 mg, and atorvastatin 80 mg) statin; or fenofibric acid 135 mg + low- or moderate-dose statin. The high-dose statin monotherapy groups enrolled half the number of patients as the other treatment arms and served as a reference arm for safety in each study. Fig. 1Design and timeline of the controlled studies and the open-label extension study. Patients with LDL-C \< 100 mg/dL but TG \>200 mg/dL after receiving moderate-dose statin monotherapy in the controlled studies, who entered and received ≥1 dose of treatment with fenofibric acid + moderate-dose statin in the 52-week extension were included in the analysis

In the extension study, all patients received fenofibric acid 135 mg + moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for up to 52 weeks. Patients in the extension study received the same statin that was used in the controlled study in which they had participated. At protocol-specified study visits, patients were evaluated for efficacy and safety measures.

Patient population {#Sec3}
------------------

The inclusion criteria specified for the present analysis required patients to: (a) have been treated with moderate-dose statin monotherapy (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for 12 weeks in one of the three controlled studies; (b) have entered and received ≥1 dose of treatment with fenofibric acid + moderate-dose statin in the 52-week open-label extension study; and (c) have LDL-C \<100 mg/dL and TG \>200 mg/dL at the start of the open-label extension study.

Efficacy and safety measures {#Sec4}
----------------------------

The efficacy measures for the present analyses were as follows: (a) percent changes in lipids (non--HDL-C, TG, LDL-C, and HDL-C) and apolipoprotein (Apo) B levels at scheduled time points in the 52-week extension study relative to start of treatment with the combination of fenofibric acid and moderate-dose statin (hereafter referred to as baseline); (b) proportion of patients achieving NCEP ATP III \[[@CR5]\] and/or consensus \[[@CR10]\] recommended optimal levels of LDL-C (\<100 mg/dL), non--HDL-C (\<130 mg/dL), ApoB (\<90 mg/dL), HDL-C (\>40 mg/dL in men and \>50 mg/dL in women) and TG (\<200 mg/dL and \<150 mg/dL) at baseline, week 12, and final visit of the extension study; and (c) proportion of patients simultaneously achieving optimal levels of LDL-C + non--HDL-C, LDL-C + HDL-C, LDL-C + non--HDL-C + ApoB, and LDL-C + non--HDL-C + ApoB + HDL-C + TG at baseline, week 12, and final visit of the extension study. Safety was evaluated based on data collected for adverse events, physical and electrocardiographic examinations, vital sign measurements, and clinical laboratory tests. The adverse events were coded using the *Medical Dictionary of Regulatory Activities* (MedDRA). Muscle-, hepatic-, and renal-related adverse events were considered as events of special interest and were identified utilizing the appropriate standard MedDRA queries.

Statistical analyses {#Sec5}
--------------------

Mean percent changes from baseline to various time points were calculated for all efficacy parameters and were compared using a paired *t*-test. The number and percentage of patients attaining optimal individual and combined targets at week 12 and final visit (week 52 or earlier) were compared with baseline using McNemar's test, a nonparametric method used to test for marginal homogeneity of categorical data with matched pairs of patients and a dichotomous variable of interest. The test assessed whether the number/proportion of patients meeting optimal targets at baseline and after addition of fenofibric acid to moderate-dose statin therapy were different. The assumptions of equality do not hold true if the *P* value is significant, at which point the proportions indicate the direction of shift. Baseline was defined as the last value prior to the start of open-label combination therapy. The last observation carried forward (LOCF) method was used to impute values for patients with missing postbaseline values in the extension study; baseline values were not carried forward.

Results {#Sec6}
=======

A total of 2,316 patients completed the three 12-week controlled studies, of which 364 were treated with moderate-dose statin monotherapy (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) in the controlled studies and received at least one dose of fenofibric acid in combination with moderate-dose statin in the open-label extension study. Of the 364 patients, 92 (25%) had LDL-C \<100 mg/dL and TG \>200 mg/dL at the start of the open-label extension study. These 92 patients serve as the subgroup for the present analyses.

Baseline characteristics of the subgroup are summarized in Table [1](#Tab1){ref-type="table"}. The majority of the patients were white (95%) and the mean age of the subgroup was 54 years. Based on the Framingham risk categorization, 41% were considered as high-risk patients. At the start of the extension study, mean baseline LDL-C, non--HDL-C, HDL-C**,** and ApoB were 78.5 mg/dL, 133.6 mg/dL, 38.8 mg/dL, and 91.5 mg/dL, respectively; median triglycerides were 249.5 mg/dL (Table [1](#Tab1){ref-type="table"}). Table 1Baseline characteristics of the subgroup populationCharacteristic*N* = 92Gender, n (%) Women39 (42.4)Race, n (%) White87 (94.6) Black3 (3.3) Other2 (2.2)Ethnicity, n (%) Hispanic10 (10.9)Age, y Mean (SD)54.5 (10.93) ≥65, n (%)16 (17.4)Tobacco use, n (%) Tobacco user26 (28.3) Former26 (28.3) Never40 (43.5)Medical history, n (%) Hypertension47 (51.1) Diabetes mellitus type 224 (26.1) Metabolic syndrome^a^69 (75.0) Coronary artery disease5 (5.4)Framingham risk category, n (%) High38 (41.3) Moderate39 (42.4) Low15 (16.3)Baseline lipids, mg/dL Low-density lipoprotein cholesterol, mean (SD)78.5 (13.64) Non--high-density lipoprotein cholesterol, mean (SD)133.6 (36.45) High-density lipoprotein cholesterol, mean (SD)38.8 (7.31) Triglycerides, median (min, max)249.5 (200.9, 2700.0) Apolipoprotein B, mean (SD)91.5 (14.19)^a^Determined according to National Cholesterol Education Program Adult Treatment Panel III definition \[[@CR5]\]

As shown in Fig. [2](#Fig2){ref-type="fig"}, addition of fenofibric acid to moderate-dose statin for 52 weeks resulted in statistically significant mean percent reductions in non--HDL-C, ApoB, and TG at each visit relative to baseline. At final visit, the mean percent reductions after the addition of fenofibric acid to moderate-dose statin in non--HDL-C, ApoB, and TG were 9.0%, 9.8%, and 37.6%, respectively (*P* \< 0.001 for all comparisons). HDL-C and LDL-C levels significantly increased at each visit relative to baseline; mean percent increases at final visit in HDL-C and LDL-C were 14.9% and 12.1%, respectively (*P* \< 0.001). Similar changes in lipid and nonlipid parameters were noted when the data were analyzed as observed (*n* = 72). Fig. 2Mean percent changes from baseline in lipid and apolipoprotein levels over 52 weeks after addition of fenofibric acid to moderate-dose statin therapy. Baseline was defined as the value at the end of 12 weeks of moderate-dose statin monotherapy in the controlled study, prior to the start of open-label combination therapy. Data reported are based on last observation carried forward method. P values comparing each visit with baseline were obtained from a paired *t*-test. Statistically significant differences observed at each time point compared with baseline (week 0) for non--HDL-C, ApoB, HDL-C, TG, and LDL-C (*P* ≤ 0.03 for all comparisons). At week 16, ApoB was not measured

Adding fenofibric acid to moderate-dose statin numerically increased the proportion of patients with optimal non--HDL-C (\<130 mg/dL) levels from 52.2% at baseline to 63.3% and 64.4% at week 12 and final visit, respectively. Also, the proportion of patients with optimal ApoB levels (\<90 mg/dL) significantly increased to 61.1% at week 12 and 66.7% at final visit, compared with 40% at baseline (*P* ≤ 0.001 for both comparisons). Optimal HDL-C levels of \>40 mg/dL in men and \>50 mg/dL in women were achieved by 33.3% of patients at week 12, and 47.8% of patients at final visit, compared with 18.9% at baseline (*P* = 0.02 and *P* \< 0.001, respectively). Additionally, the proportion of patients with TG \<200 mg/dL was 66.7% and 70% at week 12 and final visit, respectively, compared with 0% at baseline (by definition of the population). The median baseline TG for patients who achieved optimal TG (\<200 mg/dL) was 242 mg/dL (interquartile range: 227--270 mg/dL), compared with a median baseline TG of 281 mg/dL (interquartile range: 240--557 mg/dL) for those whose TG was not optimal (≥200 mg/dL). Furthermore, the proportion of patients with TG \<150 mg/dL following combination treatment was 48.9% at final visit. Finally, the proportion with LDL-C \<100 mg/dL decreased from 100% at baseline (by definition of the population) to 78.9% at final visit (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Proportion of patients with optimal levels of LDL-C (\<100 mg/dL), non--HDL-C (\<130 mg/dL), ApoB (\<90 mg/dL), HDL-C (\>40 mg/dL in men and \>50 mg/dL in women), and TG (\<200 mg/dL and \<150 mg/dL) at baseline (after 12 weeks of treatment with moderate-dose statin) and at week 12 and final visit (week 52) after addition of fenofibric acid to moderate-dose statin therapy. Data reported are based on last observation carried forward method. Statistical comparisons were not performed for LDL-C and TG since, by definition, all patients had optimal levels of LDL-C and no patients had optimal levels of TG at baseline

The proportion of patients simultaneously achieving optimal LDL-C + non--HDL-C goals numerically increased from 52.2% at baseline to 54.4% at week 12 and 60% at final visit with the addition of fenofibric acid to moderate-dose statin therapy. The proportion of patients who simultaneously achieved optimal levels of LDL-C + HDL-C was significantly higher at final visit than at baseline (38.9% vs 18.9%; *P* = 0.001). In addition, the proportion of patients simultaneously achieving optimal LDL-C + non--HDL-C + ApoB targets was significantly higher at final visit, compared with baseline (53.3% vs 37.8%; *P* = 0.007). The proportion of patients with optimal levels of all 5 parameters (LDL-C + non--HDL-C + ApoB + HDL-C + TG) was also higher at week 12 and final visit, compared with baseline (14.4% and 25.6% vs 0%) (Fig. [4](#Fig4){ref-type="fig"}). The proportion of patients attaining individual and combined targets was similar when data were analyzed as observed (*n* = 72) and the improvements noted at week 12 were sustained through week 52. Fig. 4Proportion of patients simultaneously achieving optimal levels for multiple parameters (LDL-C + non--HDL-C; LDL-C + HDL-C, LDL-C + non--HDL-C + ApoB, and LDL-C + non--HDL-C + ApoB + HDL-C + TG) at baseline (after 12 weeks of treatment with moderate-dose statin) and at week 12 and final visit (week 52) after addition of fenofibric acid to moderate-dose statin therapy. The optimal levels for each parameter were LDL-C \<100 mg/dL, non--HDL-C \<130 mg/dL, HDL-C \>40 mg/dL for men and \>50 mg/dL for women, ApoB \<90 mg/dL, and TG \<150 mg/dL. Data reported are based on last observation carried forward method. Statistical comparisons were not performed for the achievement of optimal levels of the five parameters (LDL-C + non--HDL-C + ApoB + HDL-C + TG) since, by definition, no patients had optimal levels of TG at baseline

The addition of fenofibric acid to moderate-dose statin therapy was generally well tolerated for 52 weeks. The most frequently reported adverse events (\>5%) were constipation, gastroenteritis, bronchitis, influenza, nasopharyngitis, sinusitis, upper respiratory track infection, arthralgia, back pain, muscle spasms, dizziness, headache, cough, and pharyngolaryngeal pain. The incidence of adverse events and laboratory measurements related to muscle, hepatic, and renal systems are shown in Table [2](#Tab2){ref-type="table"}. Over the 52-week treatment period, no rhabdomyolysis was reported and the incidence of myalgia (4.3%) and myositis (1.1%) was low. Increases in creatine phosphokinase (CK) \>10x upper limit of normal (ULN) was reported for 1 patient. Alanine aminotransferase (ALT) \>3x ULN on 2 consecutive occasions was reported for 1 patient; no patients had aspartate aminotransferase (AST) \>3x ULN on 2 consecutive occasions. Table 2Incidence of adverse events and laboratory measurementsIncidence, n (%)*N* = 92Hepatic ALT \>5x ULN0 (0.0) ALT \>3x ULN on 2 consecutive occasions1 (1.1) AST \>5x ULN0 (0.0) AST \>3x ULN on 2 consecutive occasions0 (0.0)Muscle CK \>5x ULN2 (2.2) CK \>10x ULN1 (1.1) Myalgia4 (4.3) Myositis1 (1.1) Rhabdomyolysis0 (0.0)Renal Creatinine \>2 mg/dL1 (1.1) Creatinine ≥50% increase from baseline and \>1x6 (6.6) ULN on a single occasion Creatinine ≥100% increase from baseline1 (1.1)*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CK* creatine phosphokinase, *ULN* upper limit of normal

Discussion {#Sec7}
==========

This post hoc analysis of a 52-week safety and efficacy study of fenofibric acid in combination with moderate-dose statin demonstrated that in patients who were at goal for LDL-C (\<100 mg/dL), but had persistent elevated TG (\>200 mg/dL) after 12 weeks of treatment with a moderate dose-statin, the long-term addition of fenofibric acid resulted in significant improvements in non--HDL-C, ApoB, HDL-C, and TG. In addition, the proportion of patients achieving optimal levels of non--HDL-C, ApoB, HDL-C, and TG, as well as combined targets of these variables and LDL-C increased from baseline to final visit with the addition of fenofibric acid to moderate-dose statin.

The NCEP ATP III guidelines recognize elevated TG as a marker of atherogenic remnant lipoproteins and increased cardiovascular risk \[[@CR5]\]. The ATP III recommends non--HDL-C, a measure of the cholesterol content in LDL, intermediate-density lipoprotein (IDL), and very--low-density lipoprotein (VLDL) as a secondary treatment target (after LDL-C) in patients with TG ≥ 200 mg/dL. Along with LDL-C and non--HDL-C, the American Diabetes Association/American College of Cardiology Foundation consensus report has recommended ApoB as both a marker for CHD risk and a target in patients with cardiometabolic risk, whose typical lipoprotein profile includes high TGs and/or low HDL-C \[[@CR10]\]. The patients in this analysis, at goal for LDL-C but with elevated TGs despite treatment with moderate-dose statin monotherapy, qualify for the addition of a niacin or a fibrate based on treatment guidelines. As such, both non--HDL-C and ApoB levels were improved from baseline to week 12 and were sustained until week 52 with the addition of fenofibric acid to moderate-dose statin therapy. Furthermore, median TG levels decreased to near 150 mg/dL at final visit and mean HDL-C levels significantly increased to \>40 mg/dL at final visit in this subgroup of patients.

In this analysis, the mean baseline LDL-C at the start of the extension study was 79 mg/dL. After the addition of fenofibric acid to moderate-dose statin therapy, mean LDL-C increased to 87 mg/dL resulting in 21.1% of patients no longer having LDL-C \<100 mg/dL at the final visit. However, the percentage of patients with optimal non--HDL-C levels (\<130 mg/dL) increased by 12% and those with optimal ApoB levels (\<90 mg/dL) increased by 27% at final visit. These results suggest that the net effect of adding fenofibric acid to moderate-dose statin therapy is an increase in LDL particle size (as measured by the increase in cholesterol content in the LDL fraction) and a reduction in atherogenic particle number as measured by ApoB. The increase in LDL-C noted in this subgroup of patients with hypertriglyceridemia is not unexpected, as baseline TGs have been shown to influence the LDL-C--lowering effect of statin + fibrate combinations (greater reductions with low baseline TGs) \[[@CR11]\]. In patients with high TG, treatment with fibrates results in an increase in measured LDL-C content, likely because of fibrate-induced increased lipolysis of TG-rich VLDL particles \[[@CR12], [@CR13]\] and/or a shift in LDL particle size \[[@CR14]--[@CR17]\]. Despite the benefits in LDL particle size and number, and improvements in other lipid parameters, a patient's CHD risk should be considered when making treatment decisions for patients whose LDL-C is \>100 mg/dL. The primary aim of treatment, according to NCEP ATP III guidelines, is to achieve LDL-C goal (\<100 mg/dL for high-risk patients, \<130 mg/dL for moderate-risk patients, and \<160 mg/dL for low-risk patients). Combination therapy may be considered to treat the secondary non--HDL-C goal in patients with TG ≥ 200 mg/dL only after the LDL-C goal has been reached.

In the present study, the proportion of patients with optimal HDL-C increased by 29%, and 70% of the patients had TG \<200 mg/dL by final visit**.** As a result, a higher percentage of patients had optimal levels of multiple parameters such as LDL-C + non--HDL-C, LDL-C + HDL-C, LDL-C + non--HDL-C + ApoB, and LDL-C + non--HDL-C + ApoB + HDL-C + TG with the addition of fenofibric acid to moderate-dose statin for 52 weeks. As TG levels at final visit remained ≥200 mg/dL in 30% of the patients, we compared the baseline TG values of patients who achieved optimal TG versus those whose TG was not optimal. Patients whose TG remained at or above the threshold at final visit started with much higher baseline TG values (median 281 mg/dL) than those whose TG dropped below the threshold (median 242 mg/dL). Although statin monotherapy is known to reduce TG levels, the final median TG of 152.0 mg/dL in our study represents a substantial reduction in TG from a baseline median of 249.5 mg/dL with the addition of fenofibric acid to moderate-dose statin therapy.

Other treatment strategies for normalizing multiple lipid parameters in patients with mixed dyslipidemia include the addition of nicotinic acid or omega 3-fatty acids to statin therapy. Both strategies have been evaluated in long-term safety and efficacy studies and have resulted in improvements of lipid parameters other than LDL-C \[[@CR18], [@CR19]\]. Addition of omega-3 fatty acids (as eicosapentaenoic acid) to statin therapy has been shown in one study to significantly reduce major coronary events in patients with hypercholesterolemia although the study did not require elevated TG for patients to enroll \[[@CR19]\], while outcomes studies are ongoing to demonstrate the incremental benefit of adding niacin to statin treatment. It should be noted that although the combination of fenofibrate and simvastatin in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study did not significantly reduce the rate of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death compared with simvastatin alone, a prespecified analysis demonstrated a 31% relative risk reduction in cardiovascular events in patients with both high TG (≥204 mg/dL) and low HDL-C (≤34 mg/dL) compared to treatment with statin alone \[[@CR20]\]. The data from ACCORD are consistent with other fibrate trials showing that a subset of patients with elevated TGs and low HDL-C have cardiovascular benefit \[[@CR21]--[@CR23]\].

As mentioned earlier, guidelines recommend non--HDL-C and ApoB as additional secondary targets in patients with TG ≥ 200 mg/dL \[[@CR5], [@CR10], [@CR24]--[@CR26]\]. The NEPTUNE II study, a national survey estimating goal attainment with statin therapy, found that achievement of the combined LDL-C + non--HDL-C targets among patients with TG ≥ 200 mg/dL ranged from 78% in the low-risk category to 27% in the high-risk category \[[@CR27]\]. In a separate post hoc study of metabolic syndrome patients, the combined target of LDL-C + non--HDL-C was achieved by 67% of patients after 6 weeks of treatment with rosuvastatin 40 mg \[[@CR28]\]. The current analysis suggests that combination therapy with fenofibric acid + moderate-dose statin may offer a strategy to improve these goal attainment observations.

Bays et al. have previously reported the safety findings for the overall population of the open-label extension study \[[@CR9]\]. The addition of fenofibric acid to moderate-dose statin for 52 weeks in the current analysis was well tolerated. The incidence of myalgia and myositis was low; no rhabdomyolysis was reported. Elevations in liver enzymes were rare in this subgroup. Incidence of CK elevations was low, as were elevations in creatinine. Similar to the overall population, no new or unexpected adverse events were observed with 52-week exposure to fenofibric acid in combination with moderate-dose statin in the present analysis.

The primary limitations of this study are the open-label nature of the extension study, the post hoc nature of the analysis, and small size (*N* = 92) of the subgroup. Other limitations of the study are that all patients were treated with combination therapy and no comparisons with placebo or individual monotherapies were made. Additionally, although this analysis evaluated the effects of adding fenofibric acid to moderate-dose statin therapy on several lipid and apolipoprotein parameters, only reductions in LDL-C has been correlated with favorable cardiovascular outcomes.

Conclusions {#Sec8}
===========

In conclusion, this analysis evaluating the efficacy and safety of adding fenofibric acid to moderate-dose statin therapy over 52 weeks in a subgroup of patients with LDL-C \< 100 mg/dL and TG \>200 mg/dL showed that the secondary treatment target of non--HDL-C, along with ApoB, TG, and HDL-C were all improved with combination therapy compared with statin monotherapy with an acceptable safety profile.
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